Overview
The Drug Enforcement Administration is the principal federal agency responsible for enforcing controlled substance laws in the United States. It sets annual production quotas for Schedule II drugs, including amphetamine-based ADHD medications, giving it direct control over pharmaceutical supply chains.
Key Facts
- Part of the U.S. Department of Justice
- Sets annual aggregate production quotas (APQs) for controlled substances
- Production quota decisions have caused or exacerbated medication shortages, particularly for stimulant medications
Newsletter Relevance
The DEA’s quota-setting power is a case study in how regulatory infrastructure can become a chokepoint. The ADHD Medication Shortage illustrates how a single agency’s administrative decisions ripple through healthcare, labor productivity, and public trust in institutions.
Connections
- ADHD Medication Shortage — DEA production quotas are a primary driver of stimulant shortages
- Food and Drug Administration — FDA regulates drug safety while DEA controls supply; their overlapping jurisdictions create policy friction
Source Appearances
- (stub — awaiting source linkage)
Open Questions
- To what extent are DEA quota decisions driven by law enforcement priorities vs. public health needs?
- Has the DEA adjusted its quota methodology in response to the shortage crisis?